MOTS-c is an experimental mitochondrial-derived peptide that is not FDA-approved for human use 7. People discuss fatigue, headache, dizziness, nausea, sleep changes, injection-site irritation, and palpitations after using it, but there are no large trials that show how often these symptoms occur or whether MOTS-c caused them. Its long-term safety is unknown 1, 2.
Wondering if NAD+ is right for you? Take the 3-min clinical quiz.
See if you qualify →What are the most common MOTS-c peptide side effects?
The honest answer is that MOTS-c side effects are not well measured. Without an approved drug label or large human safety trials, there is no reliable side-effect table or known frequency for fatigue, headache, nausea, insomnia, or palpitations. These symptoms are best treated as possible safety signals, not expected or normal reactions 1, 2.
MOTS-c is studied because it may affect mitochondrial stress signaling, AMPK activation, and glucose metabolism. Those pathways are biologically interesting, but they also make it important not to dismiss symptoms that could reflect dehydration, low food intake, low blood sugar, infection, a medication interaction, or an unrelated health problem 1, 2, 9.
Injection-site redness, swelling, or irritation
Redness, itching, tenderness, swelling, warmth, or pain after an injection can come from the needle, the solution, an allergic response, or infection. MOTS-c-specific injection-reaction rates have not been established. Spreading redness, worsening pain, drainage, or fever needs prompt medical evaluation 10.
Fatigue, low energy, or temporary energy fluctuations
Fatigue is one of the most searched MOTS-c symptoms, but controlled human studies have not shown whether MOTS-c causes it. Since MOTS-c has been studied in experimental models of cellular energy stress and AMPK signaling, a connection is biologically plausible, but not proven 1, 2.
Headache, dizziness, or lightheadedness
Headache and dizziness can have many causes, including dehydration, missed meals, anxiety, poor sleep, blood pressure changes, and low blood sugar 9. Because there is no approved MOTS-c label, clinicians cannot use a validated adverse-event rate to tell whether the peptide is responsible.
Nausea, insomnia, fever, or flu-like symptoms
Nausea, stomach discomfort, sleep disruption, and fever-like symptoms are sometimes described in discussions of experimental peptides, but MOTS-c-specific rates are unknown. Severe vomiting, intense abdominal pain, fever after an injection, confusion, or dehydration should not be managed as a routine peptide reaction 9, 10.
Heart palpitations or increased heart rate
Palpitations can feel like racing, pounding, skipping, or irregular heartbeats. They can occur with stimulants, anxiety, dehydration, thyroid disease, hypoglycemia, electrolyte problems, or an arrhythmia 9. MOTS-c heart safety has not been established in large human trials 1, 2.
| Symptom | Possible concern | When to seek care |
|---|---|---|
| Injection-site redness or swelling | Irritation, allergic reaction, or infection | If redness spreads, pain worsens, drainage appears, or fever occurs 10 |
| Fatigue or brain fog | Sleep disruption, low intake, dehydration, blood sugar changes, or another illness 9 | If severe, persistent, paired with confusion, or affecting safe driving or work 9 |
| Dizziness or lightheadedness | Low blood sugar, low blood pressure, dehydration, or another cause 9 | If fainting, chest pain, weakness, or confusion occurs 9 |
| Nausea or vomiting | Digestive illness, dehydration, or a systemic reaction 9 | If vomiting is severe, abdominal pain is intense, or fluids cannot stay down 9 |
| Palpitations | Anxiety, stimulants, low blood sugar, electrolyte changes, or heart rhythm issues 9 | Urgently for chest pain, fainting, shortness of breath, or sustained irregular heartbeat 9 |
What is MOTS-c, and why do people use it?
MOTS-c is a mitochondrial-derived peptide: a small signaling molecule encoded by mitochondrial DNA rather than the cell nucleus. Researchers study it for its possible role in metabolism, insulin sensitivity, exercise signaling, and cellular stress response, but it has no proven clinical use in humans 1, 2.
Its full name, mitochondrial open reading frame of the 12S rRNA-c, reflects where it was first identified. Mitochondria help cells make energy, but they also send signals about fuel availability and stress 1.
What research shows versus what is still unproven
- Animal evidence: In mouse studies, MOTS-c affected metabolic measures, insulin sensitivity, and exercise-related signaling 1, 3.
- Cell evidence: Experimental work links MOTS-c with AMPK activation and stress-response pathways 1, 2.
- Human evidence: Small human studies have measured MOTS-c levels in relation to exercise and aging biology, but they do not establish treatment benefits 3, 4.
- Unproven uses: Weight loss, diabetes treatment, longevity, fertility support, immune support, and athletic performance remain investigational 1, 3, 4.
Why might MOTS-c cause fatigue or brain fog?
Fatigue after MOTS-c is not explained by a proven mechanism. It may be related to sleep, food intake, dehydration, blood sugar, another medication, or an unrelated illness 9. There is no approved label that gives a typical timeline or a safe self-management plan.
Metabolic adaptation and AMPK signaling
AMPK is a cell energy sensor. It helps cells respond when fuel is limited by shifting energy use and conservation. MOTS-c has activated AMPK-related pathways in experimental research, which explains why people speculate about temporary low-energy feelings, but this theory has not been confirmed in controlled human symptom studies 1, 2.
Blood sugar changes as a possible contributor
MOTS-c research includes glucose handling and insulin sensitivity in animal models 1. For someone using insulin, a sulfonylurea, another glucose-lowering medication, fasting, or eating very little, fatigue, sweating, shaking, headache, confusion, and palpitations may overlap with hypoglycemia symptoms 9.
Online claims that MOTS-c fatigue is caused by folate-cycle or methylation changes are not clinically validated. A plausible-sounding pathway is not the same as evidence that it explains a person’s symptoms.
Can MOTS-c affect blood sugar or diabetes medications?
MOTS-c is linked to glucose metabolism in research, not approved diabetes care. Mouse studies found changes in insulin sensitivity and glucose-related measures, but this does not show that MOTS-c safely lowers blood sugar in people 1.
People with diabetes, a history of hypoglycemia, or glucose-lowering medication need licensed clinician oversight before considering any experimental metabolic peptide. Combining uncertain effects on appetite, exercise tolerance, or insulin sensitivity with existing medicines can make symptoms harder to interpret.
- Possible low-blood-sugar symptoms include sweating, shaking, sudden weakness, headache, dizziness, confusion, blurred vision, nausea, and a fast heartbeat 9.
- Severe confusion, seizure, fainting, or inability to swallow is an emergency 9.
- Do not assume these symptoms are a normal MOTS-c effect, especially if you have diabetes.
Is MOTS-c safe for the heart?
MOTS-c heart safety is unknown in large human trials. There is not enough evidence to call it safe for people with arrhythmias, cardiovascular disease, unexplained fainting, or chest symptoms 1, 2.
People with atrial fibrillation, heart failure, prior heart attack, known rhythm problems, or unexplained shortness of breath should not self-experiment with metabolic peptides. Chest pain, fainting, shortness of breath at rest, new weakness, trouble speaking, or a sustained fast or irregular heartbeat warrants urgent medical care 9.
Who should not take MOTS-c peptide?
People at higher risk should avoid self-use of MOTS-c. This includes people who are pregnant, breastfeeding, trying to conceive, receiving fertility treatment, managing diabetes or hypoglycemia, living with significant cardiovascular disease or arrhythmias, or competing under anti-doping rules.
There are no adequate human safety data to support MOTS-c use during pregnancy, breastfeeding, or fertility treatment. Its metabolic research also makes clinician review particularly important for people using insulin, sulfonylureas, GLP-1 medications, or several metabolic medicines 1, 9.
Competitive athletes should know that MOTS-c is prohibited under WADA’s 2026 rules as an AMPK activator in the metabolic modulators category 5. Check GlobalDRO, USADA, and your sport governing body before using any peptide or supplement 6.
Is MOTS-c FDA-approved or legally available?
MOTS-c has no FDA-approved drug for human use 7. It has no FDA-approved brand name, approved indication, approved generic drug name, or established human dosing standard. Products marked “research use only” are not the same as prescribed medications and should not be used as a patient-care substitute 7, 10.
On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee recommended MOTS-c for inclusion on the 503A Bulks List. The vote was advisory, not FDA approval: FDA’s final determination remains pending, so readers should verify the current listing on FDA.gov 7, 8.
How does MOTS-c compare with peptides Chia does offer?
Chia does not currently offer MOTS-c. If you are exploring longevity or metabolic-support care, our providers can instead evaluate treatments that are actually in our current catalog and decide whether any is clinically appropriate for your health history, medications, and goals.
At Chia, available options include NAD+ in injection and nasal-spray forms, glutathione in injection and nasal-spray forms, and sermorelin in injection, nasal-spray, and tablet forms. We also offer the Foundation Longevity protocol, which includes sermorelin injection, NAD+ injection, and glutathione injection. These are not MOTS-c substitutes, and a provider should assess their own risks and evidence separately.
| Option | What it is | Forms at Chia | Current starting price | Key point |
|---|---|---|---|---|
| MOTS-c | Experimental mitochondrial-derived peptide studied for metabolism signaling | Not offered by Chia | Not available through Chia | No FDA-approved human use; long-term safety is limited 7 |
| NAD+ | A molecule involved in cellular redox biology | Injection or nasal spray | From $119/mo for nasal spray; from $179/mo for injection | Requires provider review |
| Glutathione | An antioxidant involved in redox balance | Injection or nasal spray | From $179/mo | Requires provider review |
| Sermorelin | A growth-hormone-releasing hormone analog used in clinician-guided care | Injection, nasal spray, or tablets | From $179/mo for injection | Requires provider review |
| Foundation Longevity | Sermorelin Injection + NAD+ Injection + Glutathione Injection | Protocol | From $399/mo | Prescription requires medical evaluation and is not guaranteed |
For treatments we offer, care starts with an online health questionnaire and review by a licensed US provider. When clinically appropriate, medication is compounded by a US state-licensed 503A pharmacy and shipped to the patient’s door. Compounded medications are not FDA-approved.
How can patients reduce risk when researching peptides?
The lower-risk path is licensed clinical care, not self-experimentation. A clinician can review your medical history, medications, symptoms, and whether an experimental claim has enough human evidence to justify consideration.
- Avoid products labeled “research use only.” These products are not intended for patient treatment and may not have appropriate identity, sterility, potency, storage, or contamination controls 10.
- Do not self-dose or combine peptides. Overlapping effects can make fatigue, nausea, dizziness, sleep disruption, blood sugar symptoms, and palpitations harder to trace.
- Use laboratory tests and follow-up only when a clinician finds them appropriate for your health history and symptoms.
- For broader peptide safety context, read our guide to peptide side effects and our patient guide to finding a legitimate peptide source.
What peptides stack well with MOTS-c?
There is no well-tested MOTS-c peptide stack in humans. Online and compounding-practice discussions sometimes pair MOTS-c with tissue-repair or growth-hormone-axis peptides, but combination-specific safety trials are lacking. Chia does not offer MOTS-c, BPC-157, or TB-500.
MOTS-c and BPC-157 are sometimes discussed together because one is researched for metabolic signaling and the other for tissue-repair pathways. Neither is FDA-approved for human use 7. That is a mechanistic idea, not proof of a useful combination; both have major evidence gaps, and overlapping injection-related or systemic symptoms may be difficult to sort out.
MOTS-c and CJC-1295 are sometimes mentioned in longevity communities because they target different signaling systems. Neither is FDA-approved for human use 7. There are no good combination trials establishing safety, interaction risk, or benefit, so clinician oversight matters more—not less—when multiple experimental compounds are involved.
FAQ: MOTS-c peptide side effects
It may be associated with fatigue in anecdotal reports, but human studies have not established that MOTS-c causes fatigue or explained why it would occur. Fatigue can also reflect poor sleep, dehydration, low food intake, blood sugar changes, medication effects, or another illness 9.
There is no FDA-approved MOTS-c dosing schedule, treatment duration, or validated patient timeline. Websites that present a standard cycle are not relying on an approved human drug label 7.
Peptides are short chains of amino acids that can act as signals in the body. Some peptide medicines have FDA-approved uses, while others, including MOTS-c, are experimental and do not have approved indications for patient treatment 7.
People who are pregnant, breastfeeding, trying to conceive, receiving fertility treatment, managing diabetes or hypoglycemia, taking glucose-lowering medication, living with arrhythmias or significant heart disease, or competing under WADA rules should not self-use MOTS-c.
Yes. WADA lists MOTS-c as a prohibited metabolic modulator because it is an AMPK activator. Competitive athletes should verify their status through GlobalDRO, USADA, and their sport governing body.
No. Chia does not currently offer MOTS-c. We offer clinician-reviewed NAD+, glutathione, sermorelin, and select protocols when a licensed provider determines they are clinically appropriate.
References
- 1.Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015.
- 2.Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate adaptive nuclear gene expression in response to metabolic stress. Cell Metabolism. 2018.
- 3.Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021.
- 4.Fuku N, Pareja-Galeano H, Zempo H, et al. The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity? Aging Cell. 2021.
- 5.World Anti-Doping Agency. The World Anti-Doping Code International Standard: Prohibited List 2026. 2026.
- 6.United States Anti-Doping Agency. What is the MOTS-c peptide? 2026.
- 7.U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting materials and docket, July 23–24, 2026. 2026.
- 8.Drug Topics. FDA Pharmacy Compounding Advisory Committee recommends six peptides for 503A Bulks List consideration. 2026.
- 9.American Diabetes Association Professional Practice Committee. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2026. Diabetes Care. 2026.
- 10.U.S. Food and Drug Administration. Buying Medical Products Online. 2025.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if NAD+ is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
